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Abstract
Objective—To examine the short-term effects of salpingectomy during laparoscopic
hysterectomy on ovarian reserve when ovarian preservation is planned in order to determine the
feasibility of conducting this study on a large scale.
Design—Pilot Randomized controlled trial.
Setting—Tertiary care, academic medical center.
Patients—Thirty premenopausal women aged 18 to 45 years underwent laparoscopic
hysterectomy with ovarian preservation for benign indications from April 2012 to September
2012.
Intervention—Bilateral salpingectomy (n=15) versus no salpingectomy (n=15) at the time of
laparoscopic hysterectomy with ovarian preservation.
Main Outcome Measures—Antimüllerian hormone (AMH) was measured preoperatively, 4–6
weeks postoperatively, and 3 months postoperatively. Operative time and estimated blood loss
were abstracted from the medical record.
Results—Mean AMH levels were not significantly different at baseline (2.26 vs. 2.25ng/ml), 4–
6 weeks postoperatively (1.03 vs. 1.25ng/ml), or 3 months postoperatively (1.86 vs. 1.82ng/ml)
among women with salpingectomy versus no salpingectomy, respectively. There was also no
significant temporal change in mean AMH level from baseline to 3 months postoperatively (−.07
vs. −.08ng/ml) between groups. No difference in operative time (116 vs. 115min) or estimated
blood loss (70 vs. 91ml) was observed.
Conclusion—Salpingectomy at the time of laparoscopic hysterectomy with ovarian preservation
is a safe procedure that does not appear to have any short-term deleterious effects on ovarian
reserve, as measured by AMH level. Conducting a trial of this nature that is adequately powered
with long-term follow-up would be feasible and is required to definitively confirm these results.
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Introduction
Ovarian cancer is the fifth most common cause of cancer death in women, and is the leading
cause of death due to gynecologic malignancy(1). Most ovarian cancer deaths are caused by
high-grade serous carcinomas. While it has been shown that oral contraceptive use,
hysterectomy, bilateral salpingo-oophorectomy, tubal ligation, multiparity, and
breastfeeding can reduce ovarian cancer risk, the exact mechanism of this decreased risk
remains unknown. Recent evidence suggests that the majority of high-grade pelvic serous
carcinomas may actually originate in the distal fallopian tube(2–5). As a result of these
findings, performing salpingectomy at the time of hysterectomy has been proposed as a
strategy to reduce ovarian cancer risk(6).
Over 600,000 hysterectomies are performed on an annual basis for women in the United
States, with less than half receiving concurrent bilateral salpingo-oophorectomy(7, 8). When
performing a hysterectomy with planned ovarian preservation, most gynecologists do not
currently perform salpingectomy out of theoretical concern that removing the shared blood
supply between the fallopian tube and ovary will lead to decreased ovarian function and the
premature onset of menopause(5). However, the potential deleterious effects on ovarian
reserve have not been well studied. As more women decline ovarian extirpation at the time
of hysterectomy, salpingectomy stands to benefit a substantial number of women as a risk-
reduction strategy to prevent the development of high-grade pelvic serous cancers.
Demonstrating no additional risk with salpingectomy at the time of hysterectomy may
broadly change practice patterns in a meaningful way, possibly leading to a decreased
incidence of a high-mortality malignancy for which there is no effective screening test.
The objective of this study was to examine the effects of salpingectomy during laparoscopic
hysterectomy on ovarian reserve, when preservation of the ovaries was planned, by
measuring antimüllerian hormone (AMH). We also evaluated for differences in operative
time, blood loss, and complications to determine if salpingectomy poses any additional risk
beyond hysterectomy itself. This was a pilot study designed to assess the feasibility of
enrollment and follow-up and to estimate the effect size of our intervention in order to
conduct this research on a larger scale with long-term follow-up.
Materials and Methods
This study was a single-center randomized controlled trial at the University of North
Carolina Hospitals in Chapel Hill, NC. Participants were premenopausal women aged 18 to
45 years undergoing elective laparoscopic hysterectomy for benign indications with planned
preservation of the ovaries. The upper age limit was chosen to prevent selecting patients in
close proximity to menopause. Patients with a personal history of gynecologic malignancy,
known BRCA 1/BRCA 2 carriers, and non-English speaking patients were excluded from
the study. As there was no prior data on AMH assessment evaluating ovarian reserve in this
setting at the initiation of this study, we set a goal of enrolling 30 women over a 6-month
time period. The trial protocol was approved by the Institutional Review Board of the
University of North Carolina School of Medicine and registered with ClinicalTrials.gov
(NCT01578759).
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Participants were recruited after the individual physician and the patient had established the
final surgical plan. Eligible women were introduced to the study via an informational
pamphlet provided in clinic, followed by a telephone call 1–2 weeks prior to their operation
to explain the risks and benefits of participating in the study. Informed, written consent was
obtained on the day of surgery.
After consent was obtained, participants were randomly allocated to the two treatment
groups (salpingectomy vs. no salpingectomy) in an allocation ratio of 1:1. A computerized
random number generator was used to develop the allocation sequence of random, permuted
blocks of 4 and 6. Allocation concealment was maintained by having procedure indicator
cards inside sequentially numbered, opaque, sealed envelopes. An unmasked research
assistant not associated with the trial developed the randomization scheme and stuffed and
sealed the envelopes. Participants were masked to the treatment allocation until after their
operation. The physicians performing the procedures were masked to the treatment
allocation until the time of surgical incision, at which time the circulating nurse in the
operating room opened the envelope and revealed the treatment group.
All procedures were performed by surgeons in the Advanced Laparoscopy and Pelvic Pain
division, which consists of attendings and fellows with independent surgical privileges. For
patients assigned to the salpingectomy group, removal of the fallopian tubes was performed
with either monopolar or bipolar electrosurgery based on the surgeon’s preference and the
patient’s anatomy. Care was taken to avoid injury to the ovarian vessels and to divide the
mesosalpinx as close to the fallopian tube as possible. For patients assigned to the no
salpingectomy group, the fallopian tubes were divided in the proximal tubal isthmus.
Blood samples were obtained on the day of surgery prior to surgical incision in the operating
room, at the patient’s postoperative visit 4–6 weeks after surgery, and again 3 months after
surgery. After collection, whole blood specimens were fractionated on a centrifuge for 10
minutes at 3400rpm. The separated serum was collected and placed in 1ml vials and stored
at minus 30 degrees Celsius until all specimens were obtained. The frozen serum was then
shipped to the University of Southern California Reproductive Endocrine Research Lab in
Los Angeles, California for analysis. AMH was measured by the use of the Ultrasensitive
AMH/MIS ELISA kit obtained commercially from Ansh Labs (Webster, TX). The lowest
amount of AMH that can be detected with a 95% probability is 0.023ng/ml. The assay
precision (%CV) is 5.1%, 6.0% and 4.5% at 0.346ng/ml, 0.715ng/ml and 1.853ng/ml,
respectively.
Demographic variables and secondary outcomes were abstracted from each participant’s
medical record, including age, body mass index (BMI), uterine weight, history of prior tubal
sterilization, operative time, and estimated blood loss. Comparisons between continuous
variables were analyzed using the Student’s t test or Wilcoxon rank-sum test where
appropriate. Statistical significance was defined as p<.05. All analyses were carried out
according to intent-to-treat categorization. The conduct and analysis of the trial adhered to
the 2010 CONSORT guidelines(9). Statistical analyses were conducted using Stata 12.1
(StataCorp, College Station, TX).
Results
From April 2012 through September 2012, a total of 140 patients were screened for
eligibility to participate in the trial. Seventy-seven patients did not meet criteria for
participation, most of who were excluded for planned removal of one or both ovaries. Of the
63 eligible patients, 33 declined enrollment. Thirty patients agreed to participate and were
randomized: 15 to salpingectomy and 15 to no salpingectomy. One patient assigned to the
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no salpingectomy group underwent bilateral salpingo-oophorectomy because of a large
ovarian mass that had been diagnosed as a fibroid preoperatively. All other patients received
treatment according to allocation. One intraoperative complication (inferior epigastric vessel
injury) occurred, and no patients had postoperative complications. There were no
complications directly attributable to performing salpingectomy. One patient in the
salpingectomy group had a congenitally absent left ovary and fallopian tube that had not
been diagnosed prior to her operation and one patient in the no salpingectomy group was
diagnosed with well-differentiated endometrioid adenocarcinoma (FIGO Grade 1) of the
endometrium on final pathology. In the salpingectomy group, 11 (73%) subjects completed
the 4–6 week postoperative blood draw and 14 (93%) completed the 3-month postoperative
blood draw. In the no salpingectomy group, 12 (80%) completed the 4–6 week postoperative
blood draw and 13 (87%) completed the 3-month postoperative blood draw (Figure 1).
Among all study participants, the mean age was 37.2 (±4.7) years, with a mean BMI of 36.3
(±9.0) kg/m2 and mean uterine weight of 211.7 (±235.2) grams. Approximately half (53%)
had undergone prior tubal sterilization. There were no substantive differences in the baseline
characteristics of the randomized cohort (Table 1).
Mean AMH levels were not significantly different at baseline (2.26 vs. 2.25ng/ml, p=.99),
4–6 weeks postoperatively (1.03 vs. 1.25ng/ml, p=.76), and 3 months postoperatively (1.86
vs. 1.82ng/ml, p=.97) among women with salpingectomy versus no salpingectomy,
respectively (Table 2). There were also no significant temporal changes in the mean AMH
level from baseline to 3 months postoperatively (−.07 vs. −.08ng/ml, p=.98) between groups.
There was no difference in mean operative time (116 vs. 115min, p=.97) or mean blood loss
(70 vs. 91ml, p=.54) between both groups. Non-parametric testing of the data yielded
analogous results.
Discussion
This study did not detect a significant difference in ovarian reserve at 4–6 weeks and 3
months after hysterectomy among women who underwent salpingectomy compared with
women who did not receive salpingectomy, as measured by AMH level. We also did not
find a difference in the change of AMH levels between groups from baseline to 3 months
postoperatively. There was no difference in operative time or blood loss, and there were no
complications related to performing salpingectomy. We did observe a decrease in AMH
levels at the 4–6 week point that recovered to some degree by 3 months after surgery,
similar to findings in previous studies examining AMH levels after ovarian surgery(10). As
a pilot study, an a priori power calculation was not performed so the results of this study
have to be interpreted with that in mind. We found that it was feasible to enroll participants
in such a study, with nearly 50% of eligible patients consenting to participation in the study
and 90% completing follow-up at 3 months postoperatively.
Our findings are similar to the only other published studies that have addressed whether or
not salpingectomy performed concurrently with hysterectomy can lead to impaired ovarian
function(11, 12). In 2007, Sezik et al. examined the effect of salpingectomy on ovarian
reserve and stromal blood flow after abdominal hysterectomy. This study was similarly
small (24 subjects), but they also did not find a difference in ovarian reserve among women
who underwent salpingectomy versus those that did not. In this study, the authors used
surrogate markers (FSH, LH, and estradiol) of ovarian function, which required frequent
ultrasound assessment to determine early follicular phase for blood draws. In 2013, Morelli
et al. performed a retrospective comparison of women who underwent hysterectomy without
salpingectomy to women who underwent hysterectomy with salpingectomy when ovarian
preservation was maintained. This study had a larger number of patients (79 in each group),
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and found no significant difference in AMH, FSH, antral follicle count, mean ovarian
diameters, or peak systolic velocity between groups. These findings are also consistent with
studies examining ovarian response to IVF after salpingectomy for hydrosalpinges, most of
which have shown no deleterious effects on IVF outcomes(13).
The strengths of this study include the prospective and randomized design, and the use of
AMH to measure ovarian reserve after hysterectomy. AMH has emerged as a validated,
well-studied serum biomarker produced in the ovary that provides a direct measure of
ovarian reserve. Age specific norms have been established, and AMH is now used to assess
fertility, ovarian function, and predict age at menopause(14–18). AMH levels have minimal
variation throughout the menstrual cycle, and remain relatively unaffected by conditions that
alter endogenous gonadotropins(19), eliminating the need to determine when patients are in
the follicular or luteal phase after hysterectomy. All of these factors make AMH an ideal
serum marker for assessment of ovarian reserve in this setting. This study also includes
patients undergoing laparoscopic, rather than abdominal hysterectomy, which is particularly
relevant given the increased adoption of a minimally invasive approach to hysterectomy in
the United States(20).
Limitations of this study are its small sample size and lack of long-term follow up. As a pilot
study, a small cohort was appropriate and the data included here could inform a future study
powered in non-inferiority design. We had to screen 140 patients undergoing laparoscopic
hysterectomy to recruit 30 eligible participants to the study, and our follow up rate 3 months
postoperatively was 90%, giving us a sense for how long it might take to recruit an
appropriately powered study. The ideal study would follow patients through menopause and
beyond to examine potential hormonal differences and, more importantly, differences in
cancer rates. Such a study would incur substantial cost and time, and may not be clinically
feasible. We do not know if differences would begin to appear as the participants get further
out from surgery. We plan to obtain 1-year follow up data on ovarian reserve for this cohort
of patients.
While removal of the ovaries and fallopian tubes clearly results in reduced risk of pelvic
serous cancers(21), we do not yet know if the same applies to salpingectomy alone with
ovarian retention. If indeed salpingectomy resulted in decreased ovarian function, then the
decision to remove the fallopian tubes at the time of hysterectomy would involve a risk-
benefit calculation similar to the discussion of adnexectomy. But if removing the fallopian
tubes has no significant impact on ovarian function and does not complicate the
hysterectomy, it would leave little reason not to perform salpingectomy routinely. An
additional benefit would include avoidance of future operations for benign conditions of the
fallopian tube such as hydrosalpinx, paratubal cyst, or tubal prolapse(22). If current research
regarding the role of the fallopian tube in the pathogenesis of pelvic serous cancers
continues to expand, the argument to consider prophylactic salpingectomy at the time of
hysterectomy, tubal sterilization, or other elective abdominal and pelvic surgery grows
stronger. Because pelvic serous cancers affect only about 1 in 70 women in the United
States, the number needed to treat to prevent one cancer might be large. However, when one
considers the serious morbidity of the disease and the simplicity of the prevention technique,
little downside to prophylactic salpingectomy remains.
Salpingectomy at the time of laparoscopic hysterectomy with ovarian preservation did not
have any short-term deleterious effects on ovarian reserve or increase surgical risk in this
small cohort of women. Our results suggest obtaining AMH levels after hysterectomy is a
reasonable strategy for measuring ovarian reserve, and that patients are willing to participate
in enrollment and follow-up in such a study. Investigating the question more completely
would likely require a large, multi-centered trial. A randomized controlled trial of this nature
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that is adequately powered and includes long-term follow-up is needed to definitively
conclude that salpingectomy has no deleterious effects on ovarian reserve.
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Flow of participants through the trial.
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Table 1
Demographic characteristics of participants, by treatment group.
Characteristic Salpingectomy (n=15) No Salpingectomy (n=15) P
Age (y) 36.6 ± 4.5 37.8 ± 5.0 .50a
BMI (kg/m2) 34.4 ± 6.8 38.1 ± 10.7 .27a
Uterine Weight (gms) 194.9 ± 154.6 228.4 ± 300.2 .70a
Tubal Sterilization 47 60 .46b
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Table 2
Antimüllerian hormone, operative time, and estimated blood loss, by treatment group.a
Outcome Salpingectomy No Salpingectomy P
AMH (ng/ml)
  Baseline 2.26 ± 2.72 2.25 ± 2.57 .99b
  4–6 weeks postoperative 1.03 ± 1.04 1.25 ± 2.09 .76b
  3 months postoperative 1.86 ± 1.99 1.82 ± 3.12 .97b
  Δ AMH (Baseline-3 months) −.07 ± .90 −.08 ± 1.45 .98b
Operative Time (min) 115.7 ± 33 115.2 ± 44 .97b
Estimated Blood Loss (ml) 70.3 ± 50 91.3 ± 121 .54b
a
Data are means ± SD.
b
Student’s t-test.
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